Citations (147)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xinyan Yu, Chen Chen, Yi Guo, Yuling Tong, Yi Zhao, Lingyan Wu, Xue Sun, Xifeng Wu & Zhenya Song. (2021) High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China. Annals of Medicine 53:1, pages 1621-1631.
Read now
Read now
Synne Semb, Søren Neermark, Sanne Dam-Larsen, Maria Benedicte Franzmann, Jens Albrectsen, Thomas Kallemose, Ulrik Becker & Flemming Bendtsen. (2016) Presence of alcoholic steatohepatitis, but no selective histological feature, indicates an increased risk of cirrhosis and premature death. Scandinavian Journal of Gastroenterology 51:11, pages 1367-1374.
Read now
Read now
Mazen Noureddin, Alice Zhang & Rohit Loomba. (2016) Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opinion on Emerging Drugs 21:3, pages 343-357.
Read now
Read now
Roland Andersson. (2009) This month in Scandinavian Journal of Gastroenterology. Scandinavian Journal of Gastroenterology 44:10, pages 1156-1157.
Read now
Read now
Articles from other publishers (143)
Ariana L. Garza, Miryoung Lee, John Blangero, Cici X. Bauer, Stefan A. Czerwinski & Audrey C. Choh. (2024) Genetic correlations between liver fat content, metabolic health, and adiposity distribution in the Fels Longitudinal Study. Nutrition, Metabolism and Cardiovascular Diseases.
Crossref
Crossref
D. Mounika MellemputiHemanth Harish. (2023) Assessment of Non-Alcoholic Fatty Liver Disease as Risk Factor for Cardiovascular Disease. Indian Journal of Cardiovascular Disease in Women 8, pages 230-234.
Crossref
Crossref
Bao-Fei Yan, Lan-Fen Pan, Yi-Fang Quan, Qian Sha, Jing-Zheng Zhang, Yi-Feng Zhang, Li-Bing Zhou, Xi-Long Qian, Xiao-Mei Gu, Feng-Tao Li, Ting Wang, Jia Liu & Xian Zheng. (2023) Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway. World Journal of Gastroenterology 29:31, pages 4744-4762.
Crossref
Crossref
Jihye Lim, Hyunji Sang & Ha Il Kim. (2023) Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease. JHEP Reports 5:6, pages 100721.
Crossref
Crossref
Alireza Ramandi, Jacob George, Shahin Merat, Elham Jafari, Maryam Sharafkhah, Amir Reza Radmard, Alireza Nateghi Baygi, Alireza Delavari, Zahra Mohammadi, Hossein Poustchi & Reza Malekzadeh. (2023) Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial. Hepatology International.
Crossref
Crossref
Mark D. Theodoreson, Guruprasad P. Aithal, Michael Allison, Mayur Brahmania, Ewan Forrest, Hannes Hagström, Stine Johansen, Aleksander Krag, Alisa Likhitsup, Steven Masson, Anne McCune, Neil Rajoriya, Maja Thiele, Ian A. Rowe & Richard Parker. (2023) Extra‐hepatic morbidity and mortality in alcohol‐related liver disease: Systematic review and meta‐analysis. Liver International 43:4, pages 763-772.
Crossref
Crossref
Yong‐Wen Leow, Wah‐Kheong Chan, George Boon‐Bee Goh, Vincent Wai‐Sun Wong, Jian Gao Fan, Young Seok Kim, Seung Up Kim, Atsushi Nakajima, Wai‐Kay Seto, I‐Cheng Lee, Yi‐Hsiang Huang, Yoon Jun Kim, Jang Jae Young & Wan Cheng Chow. (2023) Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP‐Asia study. Journal of Viral Hepatitis 30:4, pages 319-326.
Crossref
Crossref
Hideki Fujii, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Sakura Yamamura, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Norifumi Kawada, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima & Takeshi Okanoue. (2023) Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. Clinical Gastroenterology and Hepatology 21:2, pages 370-379.
Crossref
Crossref
Claire E. Thomas, Yi‐Chuan Yu, Hung N. Luu, Renwei Wang, Pedram Paragomi, Jaideep Behari & Jian‐Min Yuan. (2022) Neutrophil‐lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non‐alcoholic fatty liver disease. Cancer Medicine 12:3, pages 3589-3600.
Crossref
Crossref
Magnus Holmer, Hannes Hagström, Ping Chen, Olof Danielsson, Myriam Aouadi, Mikael Rydén & Per Stål. (2022) Associations between subcutaneous adipocyte hypertrophy and nonalcoholic fatty liver disease. Scientific Reports 12:1.
Crossref
Crossref
Masaji Tani, Hiromitsu Maehira, Hiroya Iida, Haruki Mori, Toru Miyake & Nobuhito Nitta. (2022) The Change in the Fibrosis-4 Index for the Assessment of Liver Fibrosis After Pancreaticoduodenectomy. Pancreas 51:6, pages 624-627.
Crossref
Crossref
Yi-Ning Dai, Cheng-Fu Xu, Hong-Ying Pan, Hai-Jun Huang, Mei-Juan Chen, You-Ming Li & Chao-Hui Yu. (2022) Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease. World Journal of Clinical Cases 10:13, pages 4097-4109.
Crossref
Crossref
Eduardo Fassio, Fernando J Barreyro, M Soledad Pérez, Diana Dávila, Graciela Landeira, Gisela Gualano & Gabriela Ruffillo. (2022) Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?. World Journal of Hepatology 14:2, pages 354-371.
Crossref
Crossref
Yi-Chuan Yu, Hung N. Luu, Renwei Wang, Claire E. Thomas, Nancy W. Glynn, Ada O. Youk, Jaideep Behari & Jian-Min Yuan. (2022) Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease. Cancer Epidemiology, Biomarkers & Prevention 31:1, pages 230-235.
Crossref
Crossref
Raj Vuppalanchi, Marshall E. McCabe, Sweta R. Tandra, Siva P. Parcha, Adil Ghafoor, Leslie Schuh, Margaret M. InmanDon J. SelzerDimitrios StefanidisNaga Chalasani. (2022) Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity. Annals of Surgery 275:1, pages e174-e180.
Crossref
Crossref
Hitoshi Yoshiji, Tadashi Namisaki, Kosuke Kaji & Sven Francque. 2022. Portal Hypertension VII. Portal Hypertension VII
221
238
.
Tracey G. Simon, Bjorn Roelstraete, Rajani Sharma, Hamed Khalili, Hannes Hagström & Jonas F. Ludvigsson. (2021) Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study. Hepatology 74:5, pages 2410-2423.
Crossref
Crossref
Chang‐Hai Liu, Javier Ampuero, Michael Pavlides, Vincent Wai‐Sun Wong, Jian‐Gao Fan, Lang Bai, Hong Li, Dong‐Bo Wu, Ling‐Yun Zhou, Ling‐Yao Du, Tian‐Kuo Yang, Wei Jiang, Ying Shi, Antonio Gil‐Gómez, Wen‐Ting Zhang, Jia‐Xu Liang, Manuel Romero‐Gómez & Hong Tang. (2021) Simple non‐invasive scoring systems and histological scores in predicting mortality in patients with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 36:7, pages 1754-1768.
Crossref
Crossref
Grace Park, Sunhee Jung, Kathryn E. Wellen & Cholsoon Jang. (2021) The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease. Experimental & Molecular Medicine 53:5, pages 809-822.
Crossref
Crossref
Suchira Gallage, María García-Beccaria, Marta Szydlowska, Mohammad Rahbari, Raphael Mohr, Frank Tacke & Mathias Heikenwalder. (2021) The therapeutic landscape of hepatocellular carcinoma. Med 2:5, pages 505-552.
Crossref
Crossref
Ashish Agarwal, Alka Singh, Wajiha Mehtab, Vipin Gupta, Ashish Chauhan, Mahendra Singh Rajput, Namrata Singh, Vineet Ahuja & Govind K. Makharia. (2021) Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver. Intestinal Research 19:1, pages 106-114.
Crossref
Crossref
Aline Gottlieb, Anna-Sophia Leven, Jan-Peter Sowa, Katrin Borucki, Alexander Link, Elvan Yilmaz, Sitke Aygen, Ali Canbay & Mustafa Porsch-Özcürümez. (2021) Lipoprotein and Metabolic Profiles Indicate Similar Cardiovascular Risk of Liver Steatosis and NASH. Digestion 102:5, pages 671-681.
Crossref
Crossref
T. N. Alexandrova & O. Ya. Babak. (2020) Effects of Ademetionine on Liver Fibrosis, Level of Pentraxin-3 and Metabolic Indicators in Patients with Comorbid Course of Non-alcoholic Liver Disease and Arterial Hypertension. Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 5:6, pages 95-101.
Crossref
Crossref
Hyeok-Hee Lee, Yongin Cho, Young Ju Choi, Byung Wook Huh, Byung-Wan Lee, Eun Seok Kang, Seok Won Park, Bong-Soo Cha, Eun Jig Lee, Yong-ho Lee & Kap Bum Huh. (2020) Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Soichi Iritani, Norio Akuta, Yusuke Kawamura, Akira Kajiwara, Kayoko Kasuya, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saito, Fumitaka Suzuki, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki & Hiromitsu Kumada. (2020) Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. BMC Gastroenterology 20:1.
Crossref
Crossref
Guillermo Mazzolini, Jan-Peter Sowa, Catalina Atorrasagasti, Özlem Kücükoglu, Wing-Kin Syn & Ali Canbay. (2020) Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 9:11, pages 2458.
Crossref
Crossref
Yamini Natarajan, Jennifer R. Kramer, Xian Yu, Liang Li, Aaron P. Thrift, Hashem B. El‐Serag & Fasiha Kanwal. (2020) Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology 72:4, pages 1242-1252.
Crossref
Crossref
Maki Tobari & Etsuko Hashimoto. (2020) Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut and Liver 14:5, pages 537-545.
Crossref
Crossref
Claire Delacôte, Pierre Bauvin, Alexandre Louvet, Flavien Dautrecque, Line Carolle Ntandja Wandji, Guillaume Lassailly, Cosmin Voican, Gabriel Perlemuter, Sylvie Naveau, Philippe Mathurin & Sylvie Deuffic-Burban. (2020) A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression. Clinical Gastroenterology and Hepatology 18:10, pages 2315-2323.e6.
Crossref
Crossref
Yoshio Sumida, Masashi Yoneda, Yuya Seko, Hiroshi Ishiba, Tasuku Hara, Hidenori Toyoda, Satoshi Yasuda, Takashi Kumada, Hideki Hayashi, Takashi Kobayashi, Kento Imajo, Masato Yoneda, Toshifumi Tada, Takumi Kawaguchi, Yuichiro Eguchi, Satoshi Oeda, Hirokazu Takahashi, Eiichi Tomita, Takeshi Okanoue & Atsushi Nakajima. (2020) Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics 10:8, pages 579.
Crossref
Crossref
Patrik Nasr, Mats Fredrikson, Mattias Ekstedt & Stergios Kechagias. (2020) The amount of liver fat predicts mortality and development of type 2 diabetes in non‐alcoholic fatty liver disease. Liver International 40:5, pages 1069-1078.
Crossref
Crossref
Cyrielle Caussy. (2020) La stéatopathie dysmétabolique ou NASH : faut-il dépister les patients à haut risque atteints de diabète de type 2 ou d’obésité ?. Nutrition Clinique et Métabolisme 34:2, pages 122-129.
Crossref
Crossref
Diego García-Compeán, Jesús Zacarías Villarreal-Pérez, Manuel Enrique de la O. Cavazos, Fernando Javier Lavalle-Gonzalez, Omar David Borjas-Almaguer, Angel Noé Del Cueto-Aguilera, José Alberto González-González, Consuelo Treviño-Garza, Lourdes Huerta-Pérez & Héctor Jesús Maldonado-Garza. (2020) Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?. Annals of Hepatology 19:3, pages 258-264.
Crossref
Crossref
Zachary H. Henry & Curtis K. Argo. (2020) How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. Gastroenterology Clinics of North America 49:1, pages 45-62.
Crossref
Crossref
Minyoul Baik, Hyo Suk Nam, Ji Hoe Heo, Hyung Jong Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Hye Sun Lee, Seung Up Kim & Young Dae Kim. (2020) Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. Cerebrovascular Diseases 49:5, pages 474-480.
Crossref
Crossref
Yoosoo Chang, Juhee Cho, Yong Kyun Cho, Ara Cho, Yun Soo Hong, Di Zhao, Jiin Ahn, Chong Il Sohn, Hocheol Shin, Eliseo Guallar & Seungho Ryu. (2020) Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases. Clinical Gastroenterology and Hepatology 18:1, pages 205-215.e7.
Crossref
Crossref
Eda Kaya & Yusuf Yilmaz. 2020. Obesity and Diabetes. Obesity and Diabetes
321
333
.
Cyrielle Caussy. (2019) Should We Screen High-Risk Populations for NAFLD?. Current Hepatology Reports 18:4, pages 433-443.
Crossref
Crossref
Toshifumi Tada, Hidenori Toyoda, Yasuhiro Sone, Satoshi Yasuda, Nozomi Miyake, Takashi Kumada & Junko Tanaka. (2019) Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle‐aged patients with non‐alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 34:11, pages 2011-2018.
Crossref
Crossref
Richard Parker, Guruprasad P. Aithal, Ulrik Becker, Dermot Gleeson, Steven Masson, Judith I. Wyatt & Ian A. Rowe. (2019) Natural history of histologically proven alcohol-related liver disease: A systematic review. Journal of Hepatology 71:3, pages 586-593.
Crossref
Crossref
Narendra S. Choudhary & Ajay Duseja. (2019) Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?. Journal of Clinical and Experimental Hepatology 9:4, pages 506-514.
Crossref
Crossref
Zobair M. Younossi, Maria Stepanova, Janus Ong, Yusuf Yilmaz, Ajay Duseja, Yuichiro Eguchi, Mohamed El Kassas, Marlen Castellanos-Fernandez, Jacob George, Ira M. Jacobson, Elisabetta Bugianesi, Vincent Wai-Sun Wong, Marco Arrese, Victor de Ledinghen, Manuel Romero-Gomez, Nahum Mendez-Sanchez, Aijaz Ahmed, Robert Wong, Georgios Papatheodoridis, Lawrence Serfaty, Issah Younossi, Fatema Nader, Mariam Ziayee & Arian Afendy. (2019) Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology 17:8, pages 1625-1633.e1.
Crossref
Crossref
Leon A. Adams. (2019) End-points for drug treatment in NASH. Hepatology International 13:3, pages 253-258.
Crossref
Crossref
Marie Boyle & Quentin M. Anstee. 2019. Evidence‐based Gastroenterology and Hepatology 4e. Evidence‐based Gastroenterology and Hepatology 4e
523
546
.
Yoosoo Chang, Yong Kyun ChoJuhee ChoHyun-Suk JungKyung Eun YunJiin AhnChong Il SohnHocheol ShinSeungho Ryu. (2019) Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. American Journal of Gastroenterology 114:4, pages 620-629.
Crossref
Crossref
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel & J.A. Velarde-Ruiz Velasco. (2019) The Mexican consensus on nonalcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 84:1, pages 69-99.
Crossref
Crossref
R. Bernal-Reyes, G. Castro-Narro, R. Malé-Velázquez, R. Carmona-Sánchez, M.S. González-Huezo, I. García-Juárez, N. Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia, F. Bosques-Padilla, M. Castillo-Barradas, J.A. Chávez-Barrera, L. Cisneros-Garza, J. Flores-Calderón, D. García-Compeán, Y. Gutiérrez-Grobe, M.F. Higuera de la Tijera, D. Kershenobich-Stalnikowitz, L. Ladrón de Guevara-Cetina, J. Lizardi-Cervera, J.A. López-Cossio, S. Martínez-Vázquez, E. Márquez-Guillén, N. Méndez-Sánchez, R. Moreno-Alcantar, J.L. Poo-Ramírez, P. Ramos-Martínez, H. Rodríguez-Hernández, J.F. Sánchez-Ávila, M. Stoopen-Rometti, A. Torre-Delgadillo, G. Torres-Villalobos, R. Trejo-Estrada, M. Uribe-Esquivel & J.A. Velarde-Ruiz Velasco. (2019) Consenso mexicano de la enfermedad por hígado graso no alcohólico. Revista de Gastroenterología de México 84:1, pages 69-99.
Crossref
Crossref
Yihan Yang, Jeffrey Luk & Andre N. Sofair. 2019. Clinical Epidemiology of Chronic Liver Diseases. Clinical Epidemiology of Chronic Liver Diseases
57
74
.
Fernando Bessone, Melisa Dirchwolf, María Agustina Rodil, María Valeria Razori & Marcelo G. Roma. (2018) Review article: drug‐induced liver injury in the context of nonalcoholic fatty liver disease – a physiopathological and clinical integrated view. Alimentary Pharmacology & Therapeutics 48:9, pages 892-913.
Crossref
Crossref
Suzanne E Mahady & Leon A Adams. (2018) Burden of non‐alcoholic fatty liver disease in Australia. Journal of Gastroenterology and Hepatology 33:S1, pages 1-11.
Crossref
Crossref
Dirk J. van der Windt, Vikas Sud, Hongji Zhang, Allan Tsung & Hai Huang. (2018) The Effects of Physical Exercise on Fatty Liver Disease. Gene Expression 18:2, pages 89-101.
Crossref
Crossref
Kristine S. Alexander, Neil A. Zakai, Steven D. Lidofsky, Peter W. Callas, Suzanne E. Judd, Russell P. Tracy & Mary Cushman. (2018) Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort. PLOS ONE 13:3, pages e0194153.
Crossref
Crossref
David A. Ziegler, Jacqueline R. Janowich & Adam Gazzaley. (2018) Differential Impact of Interference on Internally- and Externally-Directed Attention. Scientific Reports 8:1.
Crossref
Crossref
Patrik Nasr, Simone Ignatova, Stergios Kechagias & Mattias Ekstedt. (2017) Natural history of nonalcoholic fatty liver disease: A prospective follow‐up study with serial biopsies. Hepatology Communications 2:2, pages 199-210.
Crossref
Crossref
Vincent Wai‐Sun Wong, Wah‐Kheong Chan, Shiv Chitturi, Yogesh Chawla, Yock Young Dan, Ajay Duseja, Jiangao Fan, Khean‐Lee Goh, Masahide Hamaguchi, Etsuko Hashimoto, Seung Up Kim, Laurentius Adrianto Lesmana, Yu‐Cheng Lin, Chun‐Jen Liu, Yen‐Hsuan Ni, Jose Sollano, Simon Kin‐Hung Wong, Grace Lai‐Hung Wong, Henry Lik‐Yuen Chan & Geoff Farrell. (2017) Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment. Journal of Gastroenterology and Hepatology 33:1, pages 70-85.
Crossref
Crossref
Kenneth Cusi. 2018. Diabetes and Exercise. Diabetes and Exercise
47
69
.
Raj Vuppalanchi, Mohammad S. Siddiqui, Mark L. Van Natta, Erin Hallinan, Danielle Brandman, Kris Kowdley, Brent A. Neuschwander‐Tetri, Rohit Loomba, Srinivas Dasarathy, Manal Abdelmalek, Edward Doo, James A. Tonascia, David E. Kleiner, Arun J. Sanyal & Naga Chalasani. (2017) Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 67:1, pages 134-144.
Crossref
Crossref
Vlad Ratziu. (2017) Back to Byzance: Querelles byzantines over NASH and fibrosis. Journal of Hepatology 67:6, pages 1134-1136.
Crossref
Crossref
Mattias Ekstedt, Patrik Nasr & Stergios Kechagias. (2017) Natural History of NAFLD/NASH. Current Hepatology Reports 16:4, pages 391-397.
Crossref
Crossref
Archana Rastogi, Saggere Muralikrishna Shasthry, Ayushi Agarwal, Chhagan Bihari, Priyanka Jain, Ankur Jindal & Shiv Sarin. (2017) Non‐alcoholic fatty liver disease – histological scoring systems: a large cohort single‐center, evaluation study. APMIS 125:11, pages 962-973.
Crossref
Crossref
Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, Kazuyuki Mizuno, Yasuhiro Sone, Tomoyuki Akita & Junko Tanaka. (2017) Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease. Hepatology Communications 1:9, pages 899-910.
Crossref
Crossref
Ajeet S. Bhadoria, Chandan K. Kedarisetty, Chhagan Bihari, Guresh Kumar, Ankur Jindal, Ankit Bhardwaj, Varsha Shasthry, Tanmay Vyas, Jaya Benjamin, Shvetank Sharma, Manoj K. Sharma & Shiv K. Sarin. (2017) Impact of family history of metabolic traits on severity of non‐alcoholic steatohepatitis related cirrhosis: A cross‐sectional study. Liver International 37:9, pages 1397-1404.
Crossref
Crossref
Koki Obara, Yohei Shirakami, Akinori Maruta, Takayasu Ideta, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Takuji Tanaka, Mitsuru Seishima & Masahito Shimizu. (2017) Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget 8:35, pages 58353-58363.
Crossref
Crossref
J. Andy Tau, Aaron P. Thrift & Fasiha Kanwal. (2017) NAFLD-Related HCC: How Should the Shift in Epidemiology Change Our Prevention and Surveillance Strategies?. Current Hepatology Reports 16:1, pages 26-32.
Crossref
Crossref
Carmen Fierbinteanu-Braticevici, Crina Sinescu, Alexandru Moldoveanu, Ana Petrisor, Sorina Diaconu, Dragos Cretoiu & Bogdan Braticevici. (2016) Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. Cell Biology and Toxicology 33:1, pages 5-14.
Crossref
Crossref
Phoenix Fung & Nikolaos Pyrsopoulos. (2017) Emerging concepts in alcoholic hepatitis. World Journal of Hepatology 9:12, pages 567.
Crossref
Crossref
Victoria T. Isaksen, Maria A. Larsen, Rasmus Goll, Jon R. Florholmen & Eyvind J. Paulssen. (2016) Hepatic steatosis, detected by hepatorenal index in ultrasonography, as a predictor of insulin resistance in obese subjects. BMC Obesity 3:1.
Crossref
Crossref
Fernando Bril & Kenneth Cusi. (2016) Nonalcoholic Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America 45:4, pages 765-781.
Crossref
Crossref
William N. Hannah & Stephen A. Harrison. (2016) Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 64:6, pages 2234-2243.
Crossref
Crossref
Zheng-Jie Xu, Jun-Ping Shi, De-Rong Yu, Li-Juan Zhu, Ji-Dong Jia & Jian-Gao Fan. (2016) Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design. Advances in Therapy 33:11, pages 2069-2081.
Crossref
Crossref
Aitana Braza‐Boïls, Josep Marí‐Alexandre, Pilar Molina, Miguel A. Arnau, Moisés Barceló‐Molina, Diana Domingo, Javier Girbes, Juan Giner, Luis Martínez‐Dolz & Esther Zorio. (2016)
Deregulated hepatic micro
RNA
s underlie the association between non‐alcoholic fatty liver disease and coronary artery disease
. Liver International 36:8, pages 1221-1229.
Crossref
Crossref
Raj Vuppalanchi & Naga Chalasani. (2016) Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. Digestive Diseases and Sciences 61:7, pages 1790-1792.
Crossref
Crossref
Zobair Younossi & Linda Henry. (2016) Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. Gastroenterology 150:8, pages 1778-1785.
Crossref
Crossref
Zachary H. Henry, Stephen H. Caldwell & Curtis K. Argo. (2016) Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease. Current Hepatology Reports 15:2, pages 117-124.
Crossref
Crossref
Timothy HardyFiona OakleyQuentin M. AnsteeChristopher P. Day. (2016) Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology: Mechanisms of Disease 11:1, pages 451-496.
Crossref
Crossref
Luis Calzadilla Bertot & Leon Adams. (2016) The Natural Course of Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 17:5, pages 774.
Crossref
Crossref
Evgin Goceri, Zarine K. Shah, Rick Layman, Xia Jiang & Metin N. Gurcan. (2016) Quantification of liver fat: A comprehensive review. Computers in Biology and Medicine 71, pages 174-189.
Crossref
Crossref
Hiroyasu Sakai. (2016) Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World Journal of Gastroenterology 22:1, pages 394.
Crossref
Crossref
Dawn M. Torres & Stephen A. Harrison. 2016. Alcoholic and Non-Alcoholic Fatty Liver Disease. Alcoholic and Non-Alcoholic Fatty Liver Disease
183
194
.
Fabio Nascimbeni & Vlad Ratziu. 2016. Alcoholic and Non-Alcoholic Fatty Liver Disease. Alcoholic and Non-Alcoholic Fatty Liver Disease
271
290
.
Amit Singal & Jorge A. Marrero. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
2146
2165
.
Don C Rockey. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
2070
2086
.
M. Shadab Siddiqui & Arun J. Sanyal. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
2056
2069
.
Paul Angulo, David E. Kleiner, Sanne Dam-Larsen, Leon A. Adams, Einar S. Bjornsson, Phunchai Charatcharoenwitthaya, Peter R. Mills, Jill C. Keach, Heather D. Lafferty, Alisha Stahler, Svanhildur Haflidadottir & Flemming Bendtsen. (2015) Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 149:2, pages 389-397.e10.
Crossref
Crossref
Ying Chen, Min Xu, Tiange Wang, Jichao Sun, Wanwan Sun, Baihui Xu, Xiaolin Huang, Yu Xu, Jieli Lu, Xiaoying Li, Weiqing Wang, Yufang Bi & Guang Ning. (2015) Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis 241:1, pages 145-150.
Crossref
Crossref
Sahil Mittal, Donna L. White, Fasiha Kanwal, Norman Sussman & Hashem B. El-Serag. (2015) Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma: How Common?. Current Hepatology Reports 14:2, pages 87-98.
Crossref
Crossref
Leon A. Adams & Vlad Ratziu. (2015) Non-alcoholic fatty liver – Perhaps not so benign. Journal of Hepatology 62:5, pages 1002-1004.
Crossref
Crossref
Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stål, Stergios Kechagias & Rolf Hultcrantz. (2015) Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up. Hepatology 61:5, pages 1547-1554.
Crossref
Crossref
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano & Tooru Shimosegawa. (2015) Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology Research 45:4, pages 363-377.
Crossref
Crossref
Stephen A. Harrison. (2015) Nonalcoholic Fatty Liver Disease and Fibrosis Progression: The Good, the Bad, and the Unknown. Clinical Gastroenterology and Hepatology 13:4, pages 655-657.
Crossref
Crossref
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano & Tooru Shimosegawa. (2015) Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Journal of Gastroenterology 50:4, pages 364-377.
Crossref
Crossref
Zobair M. Younossi, Li Zheng, Maria Stepanova, Linda Henry, Chapy Venkatesan & Alita Mishra. (2015) Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 49:3, pages 222-227.
Crossref
Crossref
Per Stål. (2015) Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World Journal of Gastroenterology 21:39, pages 11077.
Crossref
Crossref
Etsuko Hashimoto, Katsutoshi Tokushige & Jurgen Ludwig. (2014) Diagnosis and classification of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatology Research 45:1, pages 20-28.
Crossref
Crossref
Svanhildur Haflidadottir, Jon G Jonasson, Helga Norland, Sylvia O Einarsdottir, David E Kleiner, Sigrun H Lund & Einar S Björnsson. (2014) Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterology 14:1.
Crossref
Crossref
Peter Dietrich & Claus Hellerbrand. (2014) Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Practice & Research Clinical Gastroenterology 28:4, pages 637-653.
Crossref
Crossref
Noriko Oza, Hirokazu Takahashi, Yuichiro Eguchi, Yoichiro Kitajima, Takuya Kuwashiro, Eriko Ishibashi, Shunya Nakashita, Shinji Iwane, Yasunori Kawaguchi, Toshihiko Mizuta, Iwata Ozaki, Naofumi Ono, Takahisa Eguchi, Kazuma Fujimoto & Keizo Anzai. (2013) Efficacy of ezetimibe for reducing serum low‐density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non‐alcoholic fatty liver disease. Hepatology Research 44:7, pages 812-817.
Crossref
Crossref
Kathleen E. Corey & Naga Chalasani. (2014) Management of Dyslipidemia as a Cardiovascular Risk Factor in Individuals With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 12:7, pages 1077-1084.
Crossref
Crossref
Itishree Trivedi & Mary E. Rinella. (2014) NAFLD and Cardiovascular Disease: Can the Real Association Be Determined?. Current Hepatology Reports 13:2, pages 130-141.
Crossref
Crossref
Ester Vanni, Lavinia Mezzabotta & Elisabetta Bugianesi. (2014) NAFLD and Hepatocellular Carcinoma: How Big a Problem is This Really?. Current Hepatology Reports 13:2, pages 113-118.
Crossref
Crossref
Raffi Karagozian, Zoltán Derdák & György Baffy. (2014) Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 63:5, pages 607-617.
Crossref
Crossref
Hugo Perazzo, Thierry Poynard & Jean-François Dufour. (2014) The Interactions of Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. Clinics in Liver Disease 18:1, pages 233-248.
Crossref
Crossref
Ester Vanni & Elisabetta Bugianesi. (2014) Obesity and Liver Cancer. Clinics in Liver Disease 18:1, pages 191-203.
Crossref
Crossref
Robert J Wong. (2014) Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World Journal of Hepatology 6:5, pages 263.
Crossref
Crossref
Goh Eun ChungDonghee Kim. (2014) Epidemiology of Nonalcoholic Fatty Liver Disease. Korean Journal of Medicine 86:4, pages 399.
Crossref
Crossref
Silvia Fargion. (2014) Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World Journal of Gastroenterology 20:37, pages 13306.
Crossref
Crossref
Marc–Emmanuel Dumas, James Kinross & Jeremy K. Nicholson. (2014) Metabolic Phenotyping and Systems Biology Approaches to Understanding Metabolic Syndrome and Fatty Liver Disease. Gastroenterology 146:1, pages 46-62.
Crossref
Crossref
Richele L. Corrado, Dawn M. Torres & Stephen A. Harrison. (2014) Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America 98:1, pages 55-72.
Crossref
Crossref
Melissa Palmer. 2014. Integrative Weight Management. Integrative Weight Management
145
169
.
Etsuko Hashimoto, Makiko Taniai & Katsutoshi Tokushige. (2013)
Characteristics and diagnosis of
NAFLD
/
NASH
. Journal of Gastroenterology and Hepatology 28:S4, pages 64-70.
Crossref
Crossref
Laurent Castera, Valérie Vilgrain & Paul Angulo. (2013) Noninvasive evaluation of NAFLD. Nature Reviews Gastroenterology & Hepatology 10:11, pages 666-675.
Crossref
Crossref
Paul Angulo, Elisabetta Bugianesi, Einar S. Bjornsson, Phunchai Charatcharoenwitthaya, Peter R. Mills, Francisco Barrera, Svanhildur Haflidadottir, Christopher P. Day & Jacob George. (2013) Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 145:4, pages 782-789.e4.
Crossref
Crossref
Elaine Hui, Aimin Xu, Hong Bo Yang & Karen S L Lam. (2013) Obesity as the common soil of non‐alcoholic fatty liver disease and diabetes: Role of adipokines. Journal of Diabetes Investigation 4:5, pages 413-425.
Crossref
Crossref
Raluca Pais, Fréderic Charlotte, Larissa Fedchuk, Pierre Bedossa, Pascal Lebray, Thierry Poynard & Vlad Ratziu. (2013) A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of Hepatology 59:3, pages 550-556.
Crossref
Crossref
Sahil Mittal & Hashem B. El-Serag. (2013) Epidemiology of Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 47:Supplement 1, pages S2-S6.
Crossref
Crossref
Ryan M. Gill & Sanjay Kakar. (2013) Nonalcoholic Steatohepatitis. Surgical Pathology Clinics 6:2, pages 227-257.
Crossref
Crossref
Paul Angulo. 2013. Non‐Alcoholic Fatty Liver Disease. Non‐Alcoholic Fatty Liver Disease
37
45
.
. (2013) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology 19:4, pages 325.
Crossref
Crossref
Romina Lomonaco, Nishanth E. Sunny, Fernando Bril & Kenneth Cusi. (2013) Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches. Drugs 73:1, pages 1-14.
Crossref
Crossref
Madeline Erario & Zobair M. Younossi. 2013. Diet Quality. Diet Quality
61
73
.
Donna L. White, Fasiha Kanwal & Hashem B. El–Serag. (2012) Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review. Clinical Gastroenterology and Hepatology 10:12, pages 1342-1359.e2.
Crossref
Crossref
Ryuta Shigefuku, Hideaki Takahashi, Minoru Kobayashi, Hiroki Ikeda, Kotaro Matsunaga, Chiaki Okuse, Nobuyuki Matsumoto, Shiro Maeyama, Shigeru Sase, Michihiro Suzuki & Fumio Itoh. (2012) Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?. Journal of Gastroenterology 47:11, pages 1238-1247.
Crossref
Crossref
Ana C. TUYAMA & Charissa Y. CHANG. (2012) Non‐alcoholic fatty liver disease. Journal of Diabetes 4:3, pages 266-280.
Crossref
Crossref
C. D. Byrne. (2012)
Dorothy Hodgkin Lecture 2012
*
Non‐alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management
. Diabetic Medicine 29:9, pages 1098-1107.
Crossref
Crossref
Mangesh R. Pagadala & Arthur J. McCullough. (2012) The Relevance of Liver Histology to Predicting Clinically Meaningful Outcomes in Nonalcoholic Steatohepatitis. Clinics in Liver Disease 16:3, pages 487-504.
Crossref
Crossref
Dawn M. Torres, Christopher D. Williams & Stephen A. Harrison. (2012) Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 10:8, pages 837-858.
Crossref
Crossref
Phunchai Charatcharoenwitthaya, Keith D. Lindor & Paul Angulo. (2012) The Spontaneous Course of Liver Enzymes and Its Correlation in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences 57:7, pages 1925-1931.
Crossref
Crossref
T. Deleuran, H. Grønbæk, H. Vilstrup & P. Jepsen. (2012) Cirrhosis and mortality risks of biopsy‐verified alcoholic pure steatosis and steatohepatitis: a nationwide registry‐based study. Alimentary Pharmacology & Therapeutics 35:11, pages 1336-1342.
Crossref
Crossref
Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton & Arun J. Sanyal. (2012) The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:7, pages 1592-1609.
Crossref
Crossref
Naga Chalasani, Zobair Younossi, Joel E Lavine, Anna Mae Diehl, Elizabeth M Brunt, Kenneth Cusi, Michael Charlton & Arun J Sanyal. (2012) The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. American Journal of Gastroenterology 107:6, pages 811-826.
Crossref
Crossref
Anil Arora & Praveen Sharma. (2012) Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology 2:2, pages 145-155.
Crossref
Crossref
Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton & Arun J. Sanyal. (2012) The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:6, pages 2005-2023.
Crossref
Crossref
Angelo H. Paredes, Dawn M. Torres & Stephen A. Harrison. (2012) Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 16:2, pages 397-419.
Crossref
Crossref
Kenneth Cusi. (2012) Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications. Gastroenterology 142:4, pages 711-725.e6.
Crossref
Crossref
Mohamed H. Ahmed, Salma Barakat & Ahmed O. Almobarak. (2012) Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists?. Journal of Obesity 2012, pages 1-9.
Crossref
Crossref
Etsuko Hashimoto & Katsutoshi Tokushige. (2011) Hepatocellular carcinoma in non‐alcoholic steatohepatitis: Growing evidence of an epidemic?. Hepatology Research 42:1, pages 1-14.
Crossref
Crossref
Neeraj Bhala, Paul Angulo, David van der Poorten, Eric Lee, Jason M. Hui, Giorgio Saracco, Leon A. Adams, Phunchai Charatcharoenwitthaya, Joanne H. Topping, Elisabetta Bugianesi, Christopher P. Day & Jacob George. (2011) The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology 54:4, pages 1208-1216.
Crossref
Crossref
Mohamed H. Ahmed & Christopher D. Byrne. 2011. The Metabolic Syndrome. The Metabolic Syndrome
245
277
.
Paul Angulo. (2011) Trial design in NASH—realities and challenges. Nature Reviews Gastroenterology & Hepatology 8:8, pages 424-425.
Crossref
Crossref
Sombat Treeprasertsuk, Francisco Lopez-Jimenez & Keith D. Lindor. (2010) Nonalcoholic Fatty Liver Disease and the Coronary Artery Disease. Digestive Diseases and Sciences 56:1, pages 35-45.
Crossref
Crossref
Etsuko Hashimoto & Katsutoshi Tokushige. (2010) Prevalence, gender, ethnic variations, and prognosis of NASH. Journal of Gastroenterology 46:S1, pages 63-69.
Crossref
Crossref
Anna Mae Diehl. (2010) Hepatic Complications of Obesity. Gastroenterology Clinics of North America 39:1, pages 57-68.
Crossref
Crossref
Paul Angulo. (2010) Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance?. Hepatology 51:2, pages 373-375.
Crossref
Crossref